"Heart failure is a journey. We owe it to our patients to be the best possible guide for their well-being."
- Javed Butler, MD, MPH, MBA

A global heart failure curriculum centered on guidelines, evidence-based medicine & real-world data to improve patient outcomes in the management of heart failure.

Resources

New! Chronic Kidney Disease in Adults: Assessment and Management

National Institute for Health and Care Excellence. Published July 23, 2014.
PDF Download

New! KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int Suppl. 2013;3(1);2.
PDF Download

New! KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int Suppl. 2012;2(5);347-356.
PDF Download

New! GUIDELINE 11: Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in CKD

K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease

New! Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry

Brunner-La Rocca HP, Linssen GC, et al. JACC Heart Fail. 2019;7(1):13-21.

New! Mineralocorticoid Receptor Antagonist Pattern of Use in Heart Failure with Reduced Ejection Fraction: Findings from BIOSTAT-CHF

Ferreira JP, Rossignol P, Machu JL, et al. Eur J Heart Fail. 2017;19(10):1284-1293.
PDF Download

New! Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

Zannad F, McMurray JJ, Krum H, et al.; EMPHASIS-HF Study Group. N Engl J Med. 2011;364(1):11-21.
PDF Download

New! EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot)

Maggioni AP, Dahlström U, Filippatos G, et al. Eur J Heart Fail. 2010;12(10):1076-1084.
PDF Download

New! EuroHeart Failure Survey II (EHFS II): A Survey on Hospitalized Acute Heart Failure Patients: Description of Population

Nieminen MS, Brutsaert D, Dickstein K, et al. Eur Heart J. 2006;27(22):2725-2736.
PDF Download

New! The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. Randomized Aldactone Evaluation Study Investigators

Pitt B, Zannad F, Remme WJ, et al. N Engl J Med. 1999;341(10):709-717.
PDF Download

New! Management of Hyperkalaemia in Acute Kidney Injury in a Heart Failure Patient with Patiromer

Slawik J, Dederer J, Kindermann I, Böhm M. ESC Heart Fail. 2020;7(5):3161–3164.
PDF Download

New! Incidence, Predictors and CLINICAL MANAGEMENT of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists

Trevisan M, de Deco P, Xu H, et al. Eur J Heart Fail. 2018;20(8):1217-1226.
PDF Download

New! Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-angiotensin-aldosterone System Inhibitors

Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Am J Manag Care. 2015;21(11 Suppl):S212-S220.
PDF Download

New! Microalbuminuria as a Target to Improve Cardiovascular and Renal Outcomes

Basi S, Lewis JB. Am J Kidney Dis. 2006;47(6):927-946.

New! Potassium Homeostasis and Management of Dyskalemia in Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Clase CM, Carrero JJ, Ellison DH, et al. Kidney Int. 2020;97(1):42-61.
PDF Download

New! Management of Hyperkalaemia in Acute Kidney Injury in a Heart Failure Patient with Patiromer

Slawik J, Dederer J, Kindermann I, Böhm M. ESC Heart Fail. 2020;7(5):3161–3164.
PDF Download

New! A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia

Fishbane S, Ford M, Fukagawa M, et al. J Am Soc Nephrol. 2019;30(9):1723-1733.
PDF Download

New! Sodium Zirconium Cyclosilicate Among Individuals with Hyperkalemia: A 12-month Phase 3 Study

Spinowitz BS, Fishbane S, Pergola PE, et al. Clin J Am Soc Nephrol. 2019;14(6):798-809.
PDF Download

New! Long-Term Effects of Patiromer for Hyperkalaemia Treatment in Patients with Mild Heart Failure and Diabetic Nephropathy on Angiotensin-Converting Enzymes/Angiotensin Receptor Blockers: Results from AMETHYST-DN

Pitt B, Bakris GL, Weir MR, et al. ESC Heart Fail. 2018;5(4):592-602.
PDF Download

New! Incidence, Predictors and CLINICAL MANAGEMENT of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists

Trevisan M, de Deco P, Xu H, et al. Eur J Heart Fail. 2018;20(8):1217-1226.
PDF Download

New! Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project

Bandak G, Sang Y, Gasparini A, et al. J Am Heart Assoc. 2017;6(7):e005428.
PDF Download

New! Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease

Lazich I, Bakris GL. Semin Nephrol. 2014;34(3):333-339.

New! Mechanisms of Progression and Regression of Renal Lesions of Chronic Nephropathies and Diabetes

Remuzzi G, Benigni A, Remuzzi A. J Clin Invest. 2006;116(2):288-296.
PDF Download

New! Iron Deficiency in Heart Failture: Looking Beyond Anaemia

Wong CC, Ng AC, Kritharides L, Sindone AP. Heart Lung Circ. 2016;25(3):209-216.
PDF Download

New! Iron Deficiency and Heart Failure: Diagnostic Dilemmas and Therapeutic Perspectives

Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Eur Heart J. 2013;34(11):816-829.
PDF Download

New! Common Misconceptions About Iron Deficiency in Heart Failure and What to Do About It

Slides from a podcast discussing the prevalence of iron deficiency and the evidence supporting its screening and management in heart failure.

New! Ferric Carboxymaltose for Iron Deficiency at Discharge after Acute Heart Failure: A Multicentre, Double-Blind, Randomised, Controlled Trial

Ponikowski P, Kirwan B, Anker SD, et al. Lancet. Published online November 13, 2020. doi:10.1016/S0140-6736(20)32339-4
PDF Download

New! Iron Deficiency in 78 805 People Admitted with Heart Failure Across England: A Retrospective Cohort Study

Beattie JM, Khatib R, Phillips CJ, Williams SG. Open Heart. 2020;7(1):e001153.
PDF Download

New! Rationale and Design of the AFFIRM-AHF Trial: A Randomised, Double-Blind, Placebo-Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron-Deficient Patients Admitted for Acute Heart Failure

Ponikowski P, Kirwan BA, Anker SD, et al. Eur J Heart Fail. 2019;21(12):1651-1658.
PDF Download

New! Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial

Lewis GD, Malhotra R, Hernandez AF, et al. JAMA. 2017;317(19):1958-1966.
PDF Download

New! The Hepcidin Circuits Act: Balancing Iron and Inflammation

Maliken BD, Nelson JE, Kowdley KV. Hepatology. 2011;53(5):1764-1766
PDF Download

New! Iron Deficiency in Heart Failure

A comprehensive slide presentation with notes on the latest data examining the role of iron deficiency as a risk factor in heart failure. Evidence and recommendations for the use of intravenous iron to correct deficiencies and improve patient outcomes is presented.

 

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018

NHFA CSANZ Heart Failure Guidelines Working Group, Atherton JJ, Sindone A, et al. Heart Lung Circ. 2018;27(10):1123-1208.
PDF Download

Expert Consensus Document on the Management of Hyperkalaemia in Patients with Cardiovascular Disease Treated with Renin Angiotensin Aldosterone System Inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

Rosano GMC, Tamargo J, Kjeldsen KP, et al. Eur Heart J Cardiovasc Pharmacother. 2018;4(3):180-188.
PDF Download

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Yancy CW, Jessup M, Bozkurt B, et al. J Am Coll Cardiol. 2017;70(6):776-803.
PDF Download

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC

Ponikowski P, Voors AA, Anker SD, et al. Eur J Heart Fail. 2016;37(27):2129-2200.
PDF Download

2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Yancy CW, Jessup M, Bozkurt B, et al. J Am Coll Cardiol. 2016;68(13):1476-1488.
PDF Download

New! Chronic Kidney Disease in Adults: Assessment and Management

National Institute for Health and Care Excellence. Published July 23, 2014.
PDF Download

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Yancy CW, Jessup M, et al. Circulation. 2013;128(16):e240-e327.
PDF Download

New! KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int Suppl. 2013;3(1);2.
PDF Download

New! KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int Suppl. 2012;2(5);347-356.
PDF Download

New! GUIDELINE 11: Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in CKD

K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease

New! Microalbuminuria as a Target to Improve Cardiovascular and Renal Outcomes

Basi S, Lewis JB. Am J Kidney Dis. 2006;47(6):927-946.

 

Estimating Lifetime Benefits of Comprehensive Disease-Modifying Pharmacological Therapies in Patients with Heart Failure with Reduced Ejection Fraction: A Comparative Analysis of Three Randomised Controlled Trials

Vaduganathan M, Claggett BL, Jhund PS, et al. Lancet. 2020; 396(10244):121-128.

New! Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry

Brunner-La Rocca HP, Linssen GC, et al. JACC Heart Fail. 2019;7(1):13-21.

Factors Associated with Underuse of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction: An Analysis of 11 215 Patients from the Swedish Heart Failure Registry

Savarese G, Carrero JJ, Pitt B, et al. Eur J Heart Fail. 2018;20(9):1326-1334.
PDF Download

Medical Therapy for Heart Failure with Reduced Ejection Fraction: The CHAMP-HF Registry

Greene SJ, Butler J, Albert NM et al. J Am Coll Cardiol. 2018;72(4):351-366.
PDF Download

Association Between Enrolment in a Heart Failure Quality Registry and Subsequent Mortality—A Nationwide Cohort Study

Lund LH, Carrero JJ, Farahmand B, et al. Eur J Heart Fail. 2017;19(9):1107–1116.
PDF Download

New! Mineralocorticoid Receptor Antagonist Pattern of Use in Heart Failure with Reduced Ejection Fraction: Findings from BIOSTAT-CHF

Ferreira JP, Rossignol P, Machu JL, et al. Eur J Heart Fail. 2017;19(10):1284-1293.
PDF Download

European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year Follow-up Outcomes and Differences Across Regions

Crespo-Leiro MG, Anker SD, Maggioni AP, et al. Eur J Heart Fail. 2016;18(6):613-625.
PDF Download

Physicians' Adherence to Guideline-recommended Medications in Heart Failure with Reduced Ejection Fraction: Data from the QUALIFY Global Survey

Komajda M, Anker SD, Cowie MR, et al. Eur J Heart Fail. 2016;18(5):514-522.
PDF Download

New! Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

Zannad F, McMurray JJ, Krum H, et al.; EMPHASIS-HF Study Group. N Engl J Med. 2011;364(1):11-21.
PDF Download

New! EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot)

Maggioni AP, Dahlström U, Filippatos G, et al. Eur J Heart Fail. 2010;12(10):1076-1084.
PDF Download

Efficacy and Safety of Exercise Training in Patients with Chronic Heart Failure: HF-ACTION Randomized Controlled Trial.

O'Connor CM, Whellan DJ, Lee KL, et al. JAMA. 2009;301(14):1439-1450.

Use of Aldosterone Antagonists in Heart Failure

Albert NM, Yancy CW, Liang L, et al. JAMA. 2009;302(15):1658-1665.

Factors Identified as Precipitating Hospital Admissions for Heart Failure and Clinical Outcomes: Findings from OPTIMIZE-HF

Fonarow GC, Abraham WT, Albert NM, et al. Arch Intern Med. 2008;168(8):847-854.

Heart Failure Care in the Outpatient Cardiology Practice Setting: Findings from IMPROVE HF

Fonarow GC, Yancy CW, Albert NM, et al. Circ Heart Fail. 2008;1(2):98-106.
PDF Download

New! EuroHeart Failure Survey II (EHFS II): A Survey on Hospitalized Acute Heart Failure Patients: Description of Population

Nieminen MS, Brutsaert D, Dickstein K, et al. Eur Heart J. 2006;27(22):2725-2736.
PDF Download

New! The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. Randomized Aldactone Evaluation Study Investigators

Pitt B, Zannad F, Remme WJ, et al. N Engl J Med. 1999;341(10):709-717.
PDF Download

 

Unravelling the Interplay Between Hyperkalaemia, Renin-angiotensin-aldosterone Inhibitor Use and Clinical Outcomes: Data from 9222 Chronic Heart Failure Patients of the ESC-HFA-EORP Heart Failure Long-Term Registry

Rossignol P, Lainscak M, Crespo-Leiro MG, et al. Eur J Heart Fail. Published online April 3, 2020. doi:10.1002/ejhf.1793

Association Between Potassium Level and Outcomes in Heart Failure with Reduced Ejection Fraction: A Cohort Study from the Swedish Heart Failure Registry

Cooper LB, Benson L, Mentz RJ, et al. Eur J Heart Fail. Published online February 20, 2020. doi:10.1002/ejhf.1757

Cardiovascular Risk Associated with Serum Potassium in the Context of Mineralocorticoid Receptor Antagonist Use in Patients with Heart Failure and Left Ventricular Dysfunction

Rossignol P, Duarte K, Girerd N, et al. Eur J Heart Fail. Published online January 9, 2020. doi:10.1002/ejhf.1724

New! Management of Hyperkalaemia in Acute Kidney Injury in a Heart Failure Patient with Patiromer

Slawik J, Dederer J, Kindermann I, Böhm M. ESC Heart Fail. 2020;7(5):3161–3164.
PDF Download

Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review

Ferreira JP, Butler J, Rossignol P, et al. J Am Coll Cardiol. 2020;75(22):2836-2850.

Daily Home Monitoring of Potassium, Creatinine, and Estimated Plasma Volume in Heart Failure Post-discharge.

Rossignol P, Fay R, Girerd N, Zannad F. ESC Heart Fail. 2020;7(3):1257-1263.
PDF Download

Patiromer Sorbitex Calcium for Hyperkalaemia

Aust Prescr. 2020;43(1):28-29.
PDF Download

Recurrent Hyperkalaemia Management and Use of Renin–angiotensin–aldosterone System Inhibitors: A European Multi-national Targeted Chart Review

Rossignol P, Ruilope LM, Cupisti A, et al. Clin Kidney J. 2019; 13(4):714-719.
PDF Download

Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE

Roger SD, Spinowitz BS, Lerma EV, et al. Am J Nephrol. 2019;50(6):473-480.
PDF Download

Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease (AMBER): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial

Agarwal R, Rossignol P, Romero A, et al. Lancet. 2019;394(10208):1540-1550.

Sodium Zirconium Cyclosilicate Among Individuals with Hyperkalemia: A 12-month Phase 3 Study

Spinowitz BS, Fishbane S, Pergola PE, et al. Clin J Am Soc Nephrol. 2019;14(6):798-809.
PDF Download

Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors

Weir MR, Bushinsky DA, Benton WW, et al. Am J Med. 2018;131(5):555-564.e3.
PDF Download

Long-Term Effects of Patiromer for Hyperkalaemia Treatment in Patients with Mild Heart Failure and Diabetic Nephropathy on Angiotensin-Converting Enzymes/Angiotensin Receptor Blockers: Results from AMETHYST-DN

Pitt B, Bakris GL, Weir MR, et al. ESC Heart Fail. 2018;5(4):592-602.
PDF Download

New! Incidence, Predictors and CLINICAL MANAGEMENT of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists

Trevisan M, de Deco P, Xu H, et al. Eur J Heart Fail. 2018;20(8):1217-1226.
PDF Download

Potassium and the Use of Renin-Angiotensin-Aldosterone System Inhibitors in Heart Failure with Reduced Ejection Fraction: Data From BIOSTAT-CHF

Beusekamp JC, Tromp J, van der Wal HH, et al. Eur J Heart Fail. 2018;20(5):923-930.
PDF Download

Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project

Bandak G, Sang Y, Gasparini A, et al. J Am Heart Assoc. 2017;6(7):e005428.
PDF Download

Hyperkalemia in Heart Failure

Sarwar CMS, Papadimitriou L, Pitt B, et al. J Am Coll Cardiol. 2016;68(14):1575-1589.
PDF Download

Effect of Patiromer on Serum Potassium Level in Patients with Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

Bakris GL, Pitt B, Weir MR, et al. JAMA. 2015;314(2):151-161.

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

Weir MR, Bakris GL, Bushinsky DA, et al. N Engl J Med. 2015;372(3):211-221.
PDF Download

Maintenance of Serum Potassium with Sodium Zirconium Cyclosilicate (ZS-9) in Heart Failure Patients: Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

Anker SD, Kosiborod M, Zannad F, et al. Eur J Heart Fail. 2015;17(10):1050-1056.
PDF Download

New! Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-angiotensin-aldosterone System Inhibitors

Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Am J Manag Care. 2015;21(11 Suppl):S212-S220.
PDF Download

Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients with Hyperkalemia: The HARMONIZE Randomized Clinical Trial

Kosiborod M, Rasmussen HS, Lavin P, et al. JAMA. 2014;312(21):2223-2233.

New! Microalbuminuria as a Target to Improve Cardiovascular and Renal Outcomes

Basi S, Lewis JB. Am J Kidney Dis. 2006;47(6):927-946.

 

New! Potassium Homeostasis and Management of Dyskalemia in Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Clase CM, Carrero JJ, Ellison DH, et al. Kidney Int. 2020;97(1):42-61.
PDF Download

New! Management of Hyperkalaemia in Acute Kidney Injury in a Heart Failure Patient with Patiromer

Slawik J, Dederer J, Kindermann I, Böhm M. ESC Heart Fail. 2020;7(5):3161–3164.
PDF Download

New! A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia

Fishbane S, Ford M, Fukagawa M, et al. J Am Soc Nephrol. 2019;30(9):1723-1733.
PDF Download

New! Sodium Zirconium Cyclosilicate Among Individuals with Hyperkalemia: A 12-month Phase 3 Study

Spinowitz BS, Fishbane S, Pergola PE, et al. Clin J Am Soc Nephrol. 2019;14(6):798-809.
PDF Download

New! Long-Term Effects of Patiromer for Hyperkalaemia Treatment in Patients with Mild Heart Failure and Diabetic Nephropathy on Angiotensin-Converting Enzymes/Angiotensin Receptor Blockers: Results from AMETHYST-DN

Pitt B, Bakris GL, Weir MR, et al. ESC Heart Fail. 2018;5(4):592-602.
PDF Download

New! Incidence, Predictors and CLINICAL MANAGEMENT of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists

Trevisan M, de Deco P, Xu H, et al. Eur J Heart Fail. 2018;20(8):1217-1226.
PDF Download

New! Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project

Bandak G, Sang Y, Gasparini A, et al. J Am Heart Assoc. 2017;6(7):e005428.
PDF Download

New! Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease

Lazich I, Bakris GL. Semin Nephrol. 2014;34(3):333-339.

New! Mechanisms of Progression and Regression of Renal Lesions of Chronic Nephropathies and Diabetes

Remuzzi G, Benigni A, Remuzzi A. J Clin Invest. 2006;116(2):288-296.
PDF Download

 

New! Ferric Carboxymaltose for Iron Deficiency at Discharge after Acute Heart Failure: A Multicentre, Double-Blind, Randomised, Controlled Trial

Ponikowski P, Kirwan B, Anker SD, et al. Lancet. Published online November 13, 2020. doi:10.1016/S0140-6736(20)32339-4
PDF Download

New! Iron Deficiency in 78 805 People Admitted with Heart Failure Across England: A Retrospective Cohort Study

Beattie JM, Khatib R, Phillips CJ, Williams SG. Open Heart. 2020;7(1):e001153.
PDF Download

Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction

Alcaide-Aldeano A, Garay A, Alcoberro L, et al. J Clin Med. 2020;9(4):1199.
PDF Download

New! Rationale and Design of the AFFIRM-AHF Trial: A Randomised, Double-Blind, Placebo-Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron-Deficient Patients Admitted for Acute Heart Failure

Ponikowski P, Kirwan BA, Anker SD, et al. Eur J Heart Fail. 2019;21(12):1651-1658.
PDF Download

Iron Deficiency in Heart Failure: An Overview

von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. JACC Heart Fail. 2019;7(1):36-46.

Effects of Ferric Carboxymaltose on Hospitalisations and Mortality Rates in Iron-Deficient Heart Failure Patients: An Individual Patient Data Meta-Analysis

Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Eur J Heart Fail. 2018;20(1):125-133.
PDF Download

Screening, Diagnosis and Treatment of Iron Deficiency in Chronic Heart Failure: Putting the 2016 European Society of Cardiology Heart Failure Guidelines into Clinical Practice

McDonagh T, Damy T, Doehner W, et al. Eur J Heart Fail. 2018;20(12):1664-1672.
PDF Download

New! Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial

Lewis GD, Malhotra R, Hernandez AF, et al. JAMA. 2017;317(19):1958-1966.
PDF Download

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency

van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Circulation. 2017;136(15):1374-1383.
PDF Download

New! Iron Deficiency in Heart Failture: Looking Beyond Anaemia

Wong CC, Ng AC, Kritharides L, Sindone AP. Heart Lung Circ. 2016;25(3):209-216.
PDF Download

Beneficial Effects of Long-Term Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Symptomatic Heart Failure and Iron Deficiency

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Eur Heart J. 2015;36(11):657-668.
PDF Download

High Prevalence of Iron Deficiency in Patients with Acute Decompensated Heart Failure

Cohen-Solal A, Damy T, Terbah M, et al. Eur J Heart Fail. 2014;16(9):984-991.
PDF Download

New! Iron Deficiency and Heart Failure: Diagnostic Dilemmas and Therapeutic Perspectives

Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Eur Heart J. 2013;34(11):816-829.
PDF Download

Iron Deficiency in Chronic Heart Failure: An International Pooled Analysis

Klip IT, Comin-Colet J, Voors AA, et al. Am Heart J. 2013;165(4):575-582.e3.
PDF Download

Iron Deficiency Is a Key Determinant of Health-Related Quality of Life in Patients with Chronic Heart Failure Regardless of Anaemia Status

Comín‐Colet J, Enjuanes C, González G, et al. Eur J Heart Fail. 2013;15(10):1164-1172.
PDF Download

Iron Status in Patients with Chronic Heart Failure

Jankowska EA, Malyszko J, Ardehali H, et al. Eur Heart J. 2013;34(11):827-834.
PDF Download

Iron Deficiency Predicts Impaired Exercise Capacity in Patients with Systolic Chronic Heart Failure

Jankowska EA, Rozentryt P, Witkowska A, et al. J Card Fail. 2011;17(11):899-906.

New! The Hepcidin Circuits Act: Balancing Iron and Inflammation

Maliken BD, Nelson JE, Kowdley KV. Hepatology. 2011;53(5):1764-1766
PDF Download

Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency

Anker SD, Comin Colet J, Filippatos G, et al. N Engl J Med. 2009;361(25):2436-2448.
PDF Download

 

Balancing RAASi Therapy and Potassium: Understanding How it Works

A 3D mechanism of action animation exploring the relationship between the renin-angiotensin-aldosterone system and serum potassium, and how novel binders work to treat hyperkalemia.

Das Gleichgewicht zwischen RAASi-Therapie und Kalium: Die Wirkmechanismen

Hyperkaliämie ist eine schwerwiegende Komplikation, die bei Patienten mit Herzinsuffizienz häufig auftritt.

Beyond Anemia: Understanding the Significance and Treatment of Iron Deficiency

Slides from an expert interview exploring the evidence behind screening for iron deficiency in heart failure and how its treatment can alleviate heart failure symptoms.

New! Common Misconceptions About Iron Deficiency in Heart Failure and What to Do About It

Slides from a podcast discussing the prevalence of iron deficiency and the evidence supporting its screening and management in heart failure.

Don’t Be Fooled: It’s Iron Deficiency, Not Just Anemia

Slides from a podcast discussing when patients with heart failure should be screened and how to best treat those with iron deficiency.

Examining Heart Failure Management: Can We Be Doing Better?

Slides from a panel discussion on heart failure guidelines.

Iron Deficiency and Anemia: What’s the Difference?

A 3D mechanism of action animation examining the relationship between iron deficiency, anemia, and heart failure.

New! Iron Deficiency in Heart Failure

A comprehensive slide presentation with notes on the latest data examining the role of iron deficiency as a risk factor in heart failure. Evidence and recommendations for the use of intravenous iron to correct deficiencies and improve patient outcomes is presented.

Mechanismen bei Herzinsuffizienz: Die Auswirkungen von Eisenmangel

Eisenmangel ist eine häufige Komplikation bei chronischer Herzinsuffizienz und wird mit beeinträchtigter körperlicher Belastbarkeit, verringerter Lebensqualität und einem erhöhten Risiko für eine stationäre Behandlung sowie einer erhöhten Mortalität assoziiert.

Management of Heart Failure: Time to Consider New Options?

Slides from an expert interview examining the evidence around the long-term use of potassium binders to manage serum potassium levels and support treatment with guideline-directed RAASi therapy.

Potassium Binders in Heart Failure: Who, When, and How

Slides from a podcast exploring potassium monitoring strategies and how to best utilize novel potassium binders for maximum guideline-recommended RAASi therapy.

Potassium Management

A clinical guide for potassium binder use and mineralocorticoid receptor antagonist dose adjustments in response to serum potassium values.

Potassium Management in Patients at Risk for Hyperkalemia

A comprehensive slide presentation with notes on hyperkalemia as a risk marker for poor outcomes due to under-dosing of RAASi therapy. Evidence and recommendations surrounding new strategies for managing hyperkalemia in daily practice is presented.

 

AHA Heart Failure Tools and Resources for Patients

Downloadable and interactive resources for patients with heart failure including a self-management tool, symptom tracker, and questions to ask your doctor. Spanish language resources are available.

Heart Foundation of Australia Heart Failure Resources for Patients

Resources to help educate patients with heart failure which include a video series, toolkit, and booklet on how to live well with heart failure.

ESC Heartfailurematters.org Patient Education Website

Available in 10 languages, this website provides useful tools and videos for patients with heart failure and their caregivers.

Potassium and Heart Failure

An educational handout for patients on dietary considerations surrounding potassium and heart failure.